Biomarker predicts effectiveness of brain cancer treatment
This is Clark C. Chen, M.D., Ph.D., neurosurgeon, UC San Diego Health System Credit: UC San Diego School of Medicine
“Every patient diagnosed with glioblastoma is treated with a chemotherapy called temozolomide. About 15 percent of these patients derive long-lasting benefit,” said Clark C. Chen, MD, PhD, vice-chairman of Academic Affairs, Division of Neurosurgery, UC San Diego School of Medicine and the study's principal investigator.
“We need to identify which patients benefit from temozolomide and which another type of treatment. All therapies involve risk and the possibility of side-effects. Patients should not undergo therapies if there's no likelihood of benefit.”
To pinpoint which patients were most likely respond to temozolomide, the researchers studied microRNAs that control the expression of a protein called methyl-guanine-methyl-transferase or MGMT. This protein dampens the cancer-killing effect of temozolomide. Tumors with high levels of MGMT are associated with a poor response to temozolomide therapy.
The scientists systematically tested every microRNA in the human genome to identify those that suppressed MGMT expression, with the expectation that high-levels of these microRNAs in the tumor would predict improved therapeutic response to temozolomide.
“We showed that a signature of the MGMT-regulating microRNAs predicted temozolomide response in a cohort of glioblastoma patients. Validation of these results should lead to diagnostic tools to enable us to determine which patients will benefit most from temozolomide therapy,” said Chen.
In the study, the scientists also discovered that injection of the MGMT-regulating microRNAs into glioblastoma cells increased tumor sensitivity to temozolomide treatment.
“These findings establish the foundation for microRNAs-based therapies to increase the efficacy of temozolomide in glioblastoma patients,” said lead author, Valya Ramakrishnan, PhD, postdoctoral researcher, UC San Diego School of Medicine.
Contributors to this paper included Deepa Kushwaha, Dipanjan Chowdhury and Kimberly Ng of Dana-Farber Cancer Institute; Jann Sarkaria of Mayo Clinic; Tao Jiang of Tiantan Medical Center; and Tyler Steed, Thien Nguyen, Diahnn Futalan, Johnny Akers and Bob S. Carter of UC San Diego.
Funding for this research came, in part, from the Sontag Foundation, Burroughs Wellcome Foundation, Kimmel Foundation, and the Forbeck Foundation.
Media Contact
All latest news from the category: Life Sciences and Chemistry
Articles and reports from the Life Sciences and chemistry area deal with applied and basic research into modern biology, chemistry and human medicine.
Valuable information can be found on a range of life sciences fields including bacteriology, biochemistry, bionics, bioinformatics, biophysics, biotechnology, genetics, geobotany, human biology, marine biology, microbiology, molecular biology, cellular biology, zoology, bioinorganic chemistry, microchemistry and environmental chemistry.
Newest articles
Red light therapy for repairing spinal cord injury passes milestone
Patients with spinal cord injury (SCI) could benefit from a future treatment to repair nerve connections using red and near-infrared light. The method, invented by scientists at the University of…
Insect research is revolutionized by technology
New technologies can revolutionise insect research and environmental monitoring. By using DNA, images, sounds and flight patterns analysed by AI, it’s possible to gain new insights into the world of…
X-ray satellite XMM-newton sees ‘space clover’ in a new light
Astronomers have discovered enormous circular radio features of unknown origin around some galaxies. Now, new observations of one dubbed the Cloverleaf suggest it was created by clashing groups of galaxies….
